Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The event, scheduled for September 16 at 8:30 a.m. EDT, will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at a major healthcare investment conference signals growing recognition of Helus Pharma's pipeline, which targets large unmet needs in mental health. The company, the commercial operating name of Cybin Inc., focuses on developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to provide durable improvements for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. A second candidate, HLP004, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The fireside chat provides an opportunity for investors to hear directly from leadership about the company's clinical progress and strategic vision. With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs that offer durable mental health improvements. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram.
Investors seeking the latest news and updates on HELP can visit the company's newsroom at https://ibn.fm/HELP.
BioMedWire (BMW) is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, providing access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release optimization, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
